Cleveland Clinic Innovations, the business development and commercialization arm of Cleveland Clinic, announced the creation of a spinoff company to develop a breast cancer vaccine.
The company, Shield Biotech, aims to use research from Cleveland Clinic's Lerner Research Institute to test a vaccination that prevented the development of breast tumors and inhibited existing tumors' growth in certain mice. Shield Biotech will conduct two Phase I clinical trials as part of an effort to gain Food and Drug Administration approval for testing the vaccine "as an investigational new drug in proof-of-concept, first-in-human clinical trials," according to the release.
The Phase I trials will determine the safety of the vaccine in women and optimize the immune response. With FDA approval, the in-human clinical trials would test the vaccine's effectiveness in treating triple-negative breast cancer and preventing breast tumors.
The first clinical trials are expected to begin within two years and last about three years, according to the release.
More Articles on Cleveland Clinic Innovations:
Cleveland Clinic's Call Center Improves Care Access
Cleveland Clinic Inks Consultant Deal With Beijing Hospital
Cleveland Clinic Innovations Forms Joint Venture With Irish Company